Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morning versus bedtime insulin glargine timing in type 2 diabetes
IRCT20241105063603N1Phase 3Completed
- Sponsor
- Aja University of Medical Sciences
- Start
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of insulin glargine in type 2 diabetes mellitus (T2DM), sponsored by Aja University of Medical Sciences. Primary endpoints: Fasting blood sugar control rate in morning insulin glargine injection, Two-hour blood sugar control rate in morning insulin glargine injection and 2 more. Started Mar 2023; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20241105063603N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241105063603N1.